Retatrutide
Shop Retatrutide
Shop RetatrutideCode ths10 applied at checkout
Also called: LY3437943, UPB Reta (Triple Agonist), TRIUMPH
By The Health Stacks Research TeamUpdated September 24, 2026
Retatrutide is a new weight-loss medicine that is still being tested. It is a shot given once a week. It is not for sale yet in any country. Some people try to buy fake versions online or in other places, but that is not safe.
In tests, this medicine helped people lose a lot of weight. It works by copying three natural body helpers that make you feel full, keep blood sugar steady, and burn more energy. In one study, people lost up to about a quarter of their body weight. That is more than today's similar weight-loss shots.
Doctors do not know everything about it yet because big safety studies are still going on. Fake products are being sold, and some people got very sick with liver problems from them. Wait until real doctors and safety experts say it is safe and allow it to be sold.
Research-stagePhase 3 clinical trial — large-scale testing to confirm effectiveness before approval. High confidence60–79 — backed by solid sources with good corroboration across multiple citations.
Benefits
What Retatrutide Helps With
The main themes across 389 research studies, in plain language.
Weight management
Weight reduction efficacy
72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 197 underlying claimsResearch indicates substantial reductions in body weight across clinical trials, with some studies reporting decreases approaching or exceeding 25% at higher doses over extended periods.
Appetite & intake suppression
90/100Rated 90/100Source typePeer-reviewed studyIndependent sources14Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 45 underlying claimsFindings point to decreased appetite and caloric intake, potentially mediated through central nervous system pathways and delayed gastric emptying.
Body composition & fat distribution
72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 19 underlying claimsResearch highlights favorable changes in body composition, including the reduction of visceral and abdominal fat with relative preservation of lean mass.
Tissue repair & angiogenesis
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 7 underlying claimsEarly research suggests roles in promoting wound healing, vascular recruitment, and tissue protection through gene regulation.
Joint pain & physical function
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 20 underlying claimsEvidence suggests reductions in knee osteoarthritis pain and improvements in physical function scores, potentially linked to weight loss.
Liver fat reduction
72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 32 underlying claimsData indicates a significant decrease in liver fat content and biomarkers associated with metabolic liver conditions.
Anti-inflammatory & immune effects
40/100Rated 40/100Source typeVendor / seller pageIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 18 underlying claimsPreclinical and biomarker studies suggest potential anti-inflammatory actions, including the reduction of specific cytokines and modulation of immune cell activity.
Blood sugar regulation
95/100Rated 95/100Source typePeer-reviewed studyIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 62 underlying claimsStudies suggest improvements in glycemic control, including reductions in HbA1c and fasting glucose levels, as well as enhanced insulin sensitivity in Type 2 Diabetes.
Cardiovascular risk markers
72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 31 underlying claimsStudies point to improvements in cardiometabolic risk factors, including lipid profiles (triglycerides, cholesterol) and systolic blood pressure.
Neuroprotection & nerve recovery
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 5 underlying claimsAnimal studies suggest potential protective effects against cerebral ischemia and support for traumatic nerve injury recovery.
Hormonal signaling & aging biomarkers
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 4 underlying claimsResearch explores effects on growth hormone secretion, telomerase activity, and other biomarkers associated with aging and cellular longevity.
Sleep apnea & respiratory function
72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 8 underlying claimsClinical findings indicate a reduction in the severity of obstructive sleep apnea and improvements in sleep-related breathing issues.
Anti-tumor activity
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 5 underlying claimsPreclinical models indicate potential anti-tumor effects, including reductions in tumor volume and overcoming chemotherapy resistance in specific cancers.
Energy expenditure & thermogenesis
50/100Rated 50/100Source typeUnclassified sourceIndependent sources8Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 33 underlying claimsResearch suggests an increase in energy expenditure and resting metabolic rate, possibly driven by thermogenic effects and fat oxidation.
Compound stability & research integrity
50/100Rated 50/100Source typeUnclassified sourceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 4 underlying claimsTechnical data emphasizes the importance of high purity, mass-spec confirmation, and proper storage to ensure research reproducibility and compound stability.
Free: The Peptide Stack Cheat-Sheet
You just read the research on Retatrutide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- Regulatory Warning (Compounding)Moderate 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ albme.gov
- Injectable unapproved drug products can pose risks of serious harm, including serious and life-threatening conditions from bypassing body defenses against toxins and microorganismsLifeThreatening 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fda.gov
- Excessive weight lossModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ verywellhealth.com↗ self.com
- MalnutritionSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ verywellhealth.com
- Loss of muscle massModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ verywellhealth.com
- Increased risk of frailtyModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ verywellhealth.com
- FallsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ verywellhealth.com
- Gastrointestinal eventsMildReported in 3 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org↗ nature.com↗ pharmaceutical-technology.com
- Serious adverse eventsSevereReported in 3 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org↗ nature.com↗ withpower.com
- Urinary tract infectionsMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pharmaceutical-technology.com↗ pharmaceutical-journal.com
- Increased severity of side effectsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Sudden vision changesSevereReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com↗ drugdiscoverytrends.com
- Nonarteritic anterior ischemic optic neuropathy (NAION)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Retatrutide treatment discontinuation due to adverse eventsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- Retatrutide-induced vomitingModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- Survodutide gastrointestinal adverse events leading to discontinuationModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- High discontinuation rates due to adverse eventsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- High discontinuation due to adverse events at 12mg doseModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- Increased severity of side effects with retatrutideModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com↗ drugdiscoverytrends.com
- Nausea associated with retatrutideMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Dysesthesia (abnormal sense of touch causing normal sensations to feel painful)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ biospace.com
- Upper respiratory tract infectionsMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Perceived excessive weight lossModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Digestive problemsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ biopharmadive.com
- Dysesthesia (abnormal skin sensations - burning, tingling, pins and needles)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Loss of muscle mass / lean tissueModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Decreased bone mineral density / increased osteoporosis riskModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Treatment discontinuation due to adverse effectsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Excessive weight loss leading to trial discontinuationModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ verywellhealth.com
- Risk of malnutrition and loss of muscle mass from excessive weight lossSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ verywellhealth.com
- Muscle loss increasing risk of frailty, falls, and in severe cases may contribute to deathSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ verywellhealth.com
- Transient gastrointestinal events (mostly mild-to-moderate, more frequent at 8 and 12 mg)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
- Serious adverse events in 2 retatrutide-treated participants (3 events total)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
- Urinary tract infections (new safety signal)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pharmaceutical-technology.com
- Vomiting (retatrutide 12mg arm)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- Treatment discontinuation due to adverse events (retatrutide 12mg)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- Gastrointestinal adverse events leading to discontinuation (survodutide)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- High discontinuation rates due to adverse events (11% on highest dose)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- Treatment discontinuation due to adverse events (12.2% at 9mg, 18.2% at 12mg vs 4% placebo)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- Dysesthesia (abnormal sense of touch)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ biospace.com
- Perceived excessive weight loss leading to discontinuationModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ biospace.com↗ drugdiscoverytrends.com
- Treatment discontinuation due to adverse events in 11.3% of the 12mg cohort vs 4.9% placeboModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- Dysesthesia with retatrutide (unpleasant or painful sensations), occurring in more than a fifth of patients on the 20-mg dose in TRIUMPH-4, with rates rising with dose level in TRIUMPH-1Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ biospace.com
- Upper respiratory tract infection (14.2% at highest retatrutide dose)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Vomiting (rate roughly twice that seen in an earlier Zepbound trial)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Perceived excessive weight loss leading to trial discontinuationModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Adverse-event discontinuations at 18.2% (12 mg) and 12.2% (9 mg) vs 4.0% placeboModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Dysesthesia (burning, tingling or pins and needles sensation)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Treatment discontinuation due to adverse effects (11.3% at highest dose)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Nausea (retatrutide, increased severity of side effects)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Nausea with retatrutideMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Adverse-event discontinuation (12.2% at 9 mg, 18.2% at 12 mg vs 4.0% placebo)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- High adverse-event discontinuation rate (18.2% at 12 mg vs 4.0% placebo)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Nausea (retatrutide; increased severity of side effects at higher doses)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Arrhythmias (irregular heartbeats)Severe 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- Major cardiovascular complicationsLifeThreatening 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- Excessive or unwanted weight lossModerate 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- Nausea (retatrutide)MildReported in 2 sources 70/100Rated 70/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com↗ peptideguide.com
- Increased severity of side effects compared to other GLP-1 drugs (retatrutide)Moderate 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Excruciating, complicated withdrawal symptoms from medetomidineSevere 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- Loss of lean muscle massModerate 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Persistent nauseaModerate 68/100Rated 68/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- Excessive weight loss beyond intended targetModerate 68/100Rated 68/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- Potential bone mineral density declineModerate 68/100Rated 68/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Adverse events leading to discontinuationModerate 65/100Rated 65/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- Kidney stoneModerate 65/100Rated 65/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ statnews.com
- DiscontinuationModerate 65/100Rated 65/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ fiercepharma.com
- Potential adverse effects on lean body mass or bone mineral density (under evaluation)Moderate 65/100Rated 65/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ clinicaltrialsarena.com
- DysesthesiaMildReported in 6 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources6Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com↗ medscape.com↗ prnewswire.com↗ pharmaceutical-journal.com+2
- Upper respiratory tract infectionMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com↗ cnbc.com
- Gastrointestinal issues (nauseaMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- HypoglycemiaModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Increased heart rateMildReported in 13 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources13Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com↗ withpower.com↗ pspeptides.com↗ peptidesexplorer.com+9
- Cardiac arrhythmias (mild to moderate)Moderate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Mild to moderate cardiac arrhythmiasModerateReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com↗ withpower.com
- Urinary tract infectionMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com↗ cnbc.com
- Thyroid tumors (Zepbound)LifeThreatening 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Severe stomach problems (Zepbound)SevereReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com↗ finance.yahoo.com
- Kidney problems from dehydration (Zepbound)Severe 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Gallbladder problems (Zepbound)SevereReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com↗ finance.yahoo.com
- Pancreatitis (Zepbound)Severe 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Serious allergic reactions (Zepbound)Severe 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Hypoglycemia (Zepbound)Moderate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Injection site reactions (Zepbound)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Thyroid tumors including thyroid cancerLifeThreatening 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Severe stomach problemsSevereReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com↗ finance.yahoo.com
- Gallbladder problemsSevereReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com↗ finance.yahoo.com
- Inflammation of the pancreas (pancreatitis)Severe 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Hair lossMildReported in 3 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com↗ finance.yahoo.com↗ seekpeptides.com
- VomitingMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- DiarrheaMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Dysesthesia / cutaneous hyperesthesiaMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- Hypersensitivity reactionsSevereReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ peptideprices.net
- Biliary disorders (cholelithiasis, cholecystitis)Severe 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- Dysesthesia (unpleasant or painful sensations)Moderate 60/100Rated 60/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ biospace.com
- Nausea (up to 42.4% at 12 mg vs 14.8% placebo)Moderate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Diarrhea (up to 34.1% at 9 mg vs 13.5% placebo)Moderate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Constipation (up to 26.1% at 12 mg vs 10.9% placebo)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Vomiting (up to 25.3% at 12 mg vs 4.8% placebo)Moderate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Dysesthesia (up to 12.5% at 12 mg vs 0.9% placebo; generally mild to moderate, mostly resolved)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Upper respiratory tract infection (up to 14.2% at 4 mg vs 11.6% placebo)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Urinary tract infections (up to 8.8% at 9 mg vs 5.3% placebo; generally mild to moderate)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Mild nauseaMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Gastrointestinal side effects (nausea, vomiting, diarrhea) with tirzepatide, dose-dependentMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Increased risk of hypoglycemia and treatment discontinuation at tirzepatide doses of 10 mg and aboveModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Serious side effects in ~2.5% of retatrutide participants in a prior studySevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Weight regain and rising blood glucose after tirzepatide discontinuationModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Gastrointestinal issues (mild to moderate)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Dose-dependent increase in heart rate (up to 6.7 bpm)ModerateReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com↗ withpower.com
- Gastrointestinal issues (most common, generally mild to moderate)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Nausea (38.1% at 9 mg, 43.2% at 12 mg vs 10.7% placebo)Moderate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Diarrhea (34.7% and 33.1% vs 13.4% placebo)Moderate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Constipation (21.8% and 25.0% vs 8.7% placebo)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Vomiting (20.4% and 20.9% vs 0.0% placebo)Moderate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Decreased appetite (19.0% and 18.2% vs 9.4% placebo)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
- Dysesthesia (8.8% at 9 mg, 20.9% at 12 mg vs 0.7% placebo)Mild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ prnewswire.com
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get Retatrutide
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Shop Retatrutide
Code ths10 applied at checkout
Evidence
Research Citations (3)
Every claim above traces back to a source you can check — here are 3 of them.
- Source
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
TRIUMPH-1: Phase 3 trial of retatrutide in adults with obesity or overweight and weight-related comorbidity
72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Timeline
History & Milestones
Key moments in Retatrutide’s research and regulatory timeline — sourced and dated.
- The First Triple Agonist for Antiobesity: RetatrutidePublicationOct 8, 2024Related:Retatrutide
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USAPublicationAug 12, 2023Related:Retatrutide
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptPublicationSep 6, 2022Related:Retatrutide
News
Latest on Retatrutide
Dated, sourced reporting that mentions Retatrutide.
ClinicalJul 23, 2026
Lilly's triple-agonist retatrutide hits ~29% weight loss in TRIUMPH phase 3 readouts
Eli Lilly's retatrutide - a first-in-class triple GLP-1/GIP/glucagon receptor agonist - delivered bariatric-surgery-level weight loss across its phase 3 TRIUMPH program in obesity and type 2 diabetes, with the 12 mg dose achieving roughly 28.7% mean weight reduction at 68 weeks and about 30.3% (~85 lb) in a pre-specified 104-week extension with no plateau. In TRANSCEND-T2D-1, retatrutide cut HbA1c by 1.7-2.0 percentage points at 40 weeks, and up to 68% of participants hit the composite of A1c <=6.5% plus >=10% weight loss. The data position retatrutide at the top of the obesity efficacy ladder, ahead of tirzepatide and semaglutide, pending regulatory filings.
65/100Rated 65/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
MarketMay 21, 2026
Eli Lilly's retatrutide hits 28% weight loss in TRIUMPH-1 Phase 3, raising the bar for next-generation obesity drugs
On May 21, 2026, Eli Lilly reported that its triple-agonist candidate retatrutide delivered up to 28% mean weight loss among treatment completers on the 12 mg dose in the pivotal TRIUMPH-1 Phase 3 trial, which randomized roughly 2,339 people with obesity and followed them over 80 weeks. The 'triple-G' molecule — targeting GLP-1, GIP, and glucagon receptors — is positioned as a potential best-in-class challenger to semaglutide and tirzepatide. Lower-dose arms achieved about 26% (9 mg) and 19% (4 mg) mean weight loss versus 2% for placebo, and the positive topline readout was flagged as a new high-water mark for the obesity pipeline.
70/100Rated 70/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
ConsumerJun 27, 2025
Reuters: Americans are importing raw GLP-1 powders from China and mixing their own weight-loss shots
A June 2025 Reuters investigation details a fast-growing "gray market" in which Americans import bulk semaglutide, tirzepatide, retatrutide, and cagrilintide powders from Chinese vendors — labeled as research materials — and reconstitute them into injectable weight-loss drugs at home for roughly one-tenth of the brand-name price. Buyers coordinate on Reddit and Telegram (one group, StairwayToGray, surpassed 21,000 members), pooling money for third-party purity testing. Eli Lilly and Novo Nordisk call the practice dangerous and illicit, and 38 state attorneys general asked the FDA to intervene. One profiled user overdosed after a self-dosing miscalculation, highlighting the absence of medical oversight.
72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
MarketJun 5, 2025
Novo Nordisk led the weight loss drug boom. Now it's catch-up time
STAT reports that Novo Nordisk previously shelved a promising triple agonist targeting GLP-1, GIP, and glucagon due to safety concerns, allowing Eli Lilly to advance its own candidate, retatrutide. While Novo focused on semaglutide (Wegovy), the decision highlights a conservative corporate culture that may have cost them their lead in the obesity market as retatrutide progresses through late-stage trials.
72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
RegulatoryDec 17, 2024
FDA Roundup: December 17, 2024
The FDA sent warning letters to five companies for selling unapproved GLP-1 peptide products, including semaglutide, tirzepatide, and retatrutide, in interstate commerce. One company, Veronvy, was cited for misbranded oral GLP-1 products falsely claiming FDA approval. The letters target peptide vendors Xcel Peptides, Swisschems, Summit Research, and Prime Peptides. This is part of ongoing FDA enforcement against unapproved GLP-1 sales amid high demand for these drugs.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
Wondering how Retatrutide pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Related on The Health Stacks
Explore by goal
Related peptides